Docoh
Loading...

DHR Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Company profile

DHR stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

24 Feb 21
21 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Oct 20 Jul 20 Apr 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Danaher earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.04B 6.04B 6.04B 6.04B 6.04B 6.04B
Cash burn (monthly) (positive/no burn) 1.16B (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 4.28B n/a n/a n/a n/a
Cash remaining n/a 1.75B n/a n/a n/a n/a
Runway (months of cash) n/a 1.5 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Feb 21 Mitchell P Rales Common Stock, par value $.01 Buy Aquire P Yes No 221.46 900 199.31K 3,156
26 Feb 21 Mitchell P Rales Common Stock, par value $.01 Buy Aquire P Yes No 221.46 900 199.31K 3,156
26 Feb 21 Mitchell P Rales Common Stock, par value $.01 Buy Aquire P No No 221.59 4,800 1.06M 2,409,190
24 Feb 21 Gutierrez-Ramos Jose-Carlos Common Stock Grant Aquire A No No 223 2,545 567.54K 2,545
24 Feb 21 Gutierrez-Ramos Jose-Carlos Employee Stock Option Common Stock Grant Aquire A No No 223 13,190 2.94M 13,190
24 Feb 21 Lalor Angela S Common Stock Payment of exercise Dispose F No No 223 2,539 566.2K 34,839
24 Feb 21 Lalor Angela S Employee Stock Option Common Stock Grant Aquire A No No 223 18,800 4.19M 18,800
24 Feb 21 King William Common Stock Payment of exercise Dispose F No No 223 1,671 372.63K 24,417
24 Feb 21 King William Employee Stock Option Common Stock Grant Aquire A No No 223 14,510 3.24M 14,510
24 Feb 21 Jennifer Honeycutt Common Stock Payment of exercise Dispose F No No 223 835 186.21K 8,098

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

78.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1729 1591 +8.7%
Opened positions 224 134 +67.2%
Closed positions 86 84 +2.4%
Increased positions 594 501 +18.6%
Reduced positions 691 724 -4.6%
13F shares
Current Prev Q Change
Total value 123.97B 119.16B +4.0%
Total shares 558.01M 553.58M +0.8%
Total puts 2.22M 1.25M +78.1%
Total calls 2.4M 1.29M +86.2%
Total put/call ratio 0.9 1.0 -4.4%
Largest owners
Shares Value Change
Vanguard 48.74M $10.83B -0.8%
BLK Blackrock 45.71M $10.15B +4.0%
TROW T. Rowe Price 31.36M $6.96B -11.1%
FMR 31.14M $6.92B +3.8%
STT State Street 25.39M $5.64B -3.1%
Wellington Management 21.24M $4.72B -14.4%
Massachusetts Financial Services 14.35M $3.19B -8.0%
MS Morgan Stanley 13.65M $3.03B +5.4%
BAC Bank Of America 11.82M $2.63B +0.3%
Geode Capital Management 9.69M $2.15B +3.5%
Largest transactions
Shares Bought/sold Change
Norges Bank 7.35M +7.35M NEW
Edgewood Management 8.36M +4.37M +109.5%
TROW T. Rowe Price 31.36M -3.92M -11.1%
Wellington Management 21.24M -3.56M -14.4%
BLK Blackrock 45.71M +1.77M +4.0%
1832 Asset Management 919.14K -1.46M -61.3%
Massachusetts Financial Services 14.35M -1.24M -8.0%
D1 Capital Partners 2.58M +1.21M +88.2%
Ubs Global Asset Management Americas 3.1M -1.18M -27.6%
FMR 31.14M +1.14M +3.8%

Financial report summary

?
Risks
  • The COVID-19 pandemic has adversely impacted, and continues to pose risks to, certain elements of our business and our financial statements, the nature and extent of which are highly uncertain and unpredictable.
  • We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
  • Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation.
  • The health care industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business and financial statements.
  • International economic, political, legal, compliance, social and business factors can negatively affect our business and financial statements.
  • Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
  • Certain of our businesses rely on relationships with collaborative partners and other third-parties for development, supply and marketing of certain products, potential products and technologies, and such collaborative partners or other third-parties could fail to perform sufficiently.
  • Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.
  • Our acquisition of businesses, investments, joint ventures and other strategic relationships could negatively impact our business and financial statements.
  • The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
  • Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or our predecessors have disposed could adversely affect our business and financial statements.
  • Potential indemnification liabilities pursuant to the Communications Disposition, the Fortive Disposition or the Envista Disposition could materially and adversely affect our business and financial statements.
  • We could incur significant liability if any of the Communications Disposition, the Fortive Disposition or the Envista Disposition is determined to be a taxable transaction.
  • A significant disruption in, or breach in security of, our information technology systems or data or violation of data privacy laws can adversely affect our business and financial statements.
  • Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can adversely affect our business and financial statements.
  • If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
  • The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.
  • If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our business and financial statements may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.
  • Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, key distributors and other channel partners can adversely affect our business and financial statements.
  • Our financial results are subject to fluctuations in the cost and availability of commodities that we use in our operations.
  • Our restructuring actions can have long-term adverse effects on our business and financial statements.
  • Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and results of operations.
  • If we are unable to adequately protect our intellectual property, or if third-parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable to the United States.
  • Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
  • The U.S. government has certain rights to use and disclose some of the intellectual property that we license and could exclusively license it to a third-party if we fail to achieve practical application of the intellectual property.
  • Our outstanding debt has increased significantly as a result of the Cytiva Acquisition, and we may incur additional debt in the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect our business and financial statements.
  • We may be required to recognize impairment charges for our goodwill and other intangible assets.
  • Foreign currency exchange rates can adversely affect our financial statements.
  • Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In addition, audits by tax authorities can result in additional tax payments for prior periods.
  • Changes in tax law relating to multinational corporations could adversely affect our tax position.
  • Legal, political, and economic uncertainty surrounding the exit of the United Kingdom (“UK”) from the EU could have an adverse effect on our business and financial statements.
  • Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements.
  • Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, particularly China, can have an adverse effect on our business and financial statements.
  • Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.
  • Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our business and financial statements.
  • We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
  • Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.
  • Our products are subject to clinical trials, the results of which may be unexpected, or perceived as unfavorable by the market, and could adversely affect our business and financial statements.
  • Off-label marketing of our products could result in substantial penalties.
  • Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products.
  • Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our business and financial statements.
  • Changes in governmental regulations can reduce demand for our products or services or increase our expenses.
Management Discussion
  • Total sales increased 24.5% on a year-over-year basis in 2020 primarily as a result of an increase in sales from acquired businesses, net of divestitures, primarily due to the acquisition of Cytiva, as well as an increase in core sales resulting from the factors discussed below by segment. The impact of currency translation did not have a significant impact on reported sales on a year-over-year basis in 2020 as the negative impact of a stronger U.S. dollar in the first half of 2020 was offset by the favorable impact of the weakening of the U.S. dollar in the second half of 2020.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Bad
New words: AbbVie, ABO, accessing, acquiree, aid, architecture, Asian, aspect, attack, BARDA, baseline, bioprocessing, Black, bore, broadening, built, candidate, capability, career, cent, certainty, childcare, CMS, coaching, confirm, contributor, cooperation, culture, curb, cybersecurity, daily, deeply, departure, deploying, deposit, depressed, descent, developmental, distancing, divestiture, division, DPA, EHS, elder, eldercare, enterprise, envisioned, evolve, evolved, evolving, explaining, felt, female, fill, filled, fuel, gender, guideline, healthy, hiring, home, Honeycutt, idea, Immune, incomplete, internationally, Jennifer, job, Latinx, launched, learning, LGBTQ, Listen, logo, macroeconomic, media, mental, mentoring, mentorship, misapplied, motivate, movement, nearest, negligible, obsolescence, optimize, orthe, outage, overcharged, PBO, people, permissible, philosophy, postponed, precautionary, premature, prevalence, primer, proactively, probe, profile, protectionism, proximity, race, ratified, recession, recruiting, recurrence, relaxed, reopening, Repertoire, resume, reward, rewarded, riot, rooted, royalty, Scientific, sequential, sequentially, shortage, situation, solution, stage, staggered, subside, subsided, supervisor, survey, surveyed, Synlogic, tailored, Talk, Team, temperature, therewith, thrive, toolkit, travel, tutoring, Underpinned, underrepresented, unprecedented, unsanctioned, upgrade, vaccine, waiting, wearing, Women
Removed: aliquotting, called, challenge, characteristic, claimed, clarified, clarity, column, coverslipping, Delaware, disaggregate, discontinue, discontinuing, distributing, DMG, expired, feet, flat, Florida, Genetix, histology, Hong, insight, Italy, jointly, Joyce, Jr, judgmental, Kong, lessor, lost, master, MEDIABEACON, medium, Medtronic, membership, Mortgage, narrative, nonmonetary, obligated, page, progressively, ranking, reached, reader, referendum, reincorporated, renewing, reorganized, restorative, returned, revaluation, shortening, spectrum, square, stemming, sublet, subtotal, suitable, SURGIPATH, tariff, terminal, unchanged, unfulfilled, unusual, vacate, voted

Patents

GRANT
Utility
Charge electrode
13 Apr 21
There is provided a charge electrode for charging ink droplets for continuous ink jet printing.
APP
Utility
Apparatus for Fluid Line Management In a Bioprocessing System
8 Apr 21
In an embodiment, a tubing module for a bioprocessing system includes a first tubing holder block configured to receive at least one pump tube and hold the at least one pump tube in position for selective engagement with a peristaltic pump, a second tubing holder block configured to receive a plurality of pinch valve tubes and hold each pinch valve tube of the plurality of pinch valve tubes in position for selective engagement with a respective actuator of a pinch valve array, and wherein the first tubing holder block and the second tubing holder block are interconnected.
APP
Utility
Bioprocessing Apparatus
8 Apr 21
An apparatus for bioprocessing includes a housing, a drawer receivable within the housing, the drawer including a plurality of sidewalls and a bottom defining a processing chamber, and a generally open top, the drawer being movable between a closed position in which the drawer is received within the housing, and an open position in which the drawer extends from the housing enabling access to the processing chamber through the open top, and at least one bed plate positioned within the processing chamber and configured to receive a bioreactor vessel.
APP
Utility
Bioprocessing Vessel
8 Apr 21
A bioreactor vessel includes a bottom plate, a vessel body coupled to the bottom plate, the vessel body and the bottom plate defining an interior compartment therebetween, and a plurality of recesses formed in the bottom plate, each recess of the plurality of recesses being configured to receive a corresponding alignment pin on a bed plate for aligning the bioreactor vessel on the bed plate.
APP
Utility
Nucleic Acid Elution
8 Apr 21
This invention relates to the storage on a solid matrix of genetic material, in particular DNA that has been purified prior to the application to the solid matrix.